p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD

► COPD causes significant morbidity and mortality throughout the world. ► Drugs that target inflammation have promise as therapies for COPD. ► TNF alpha, NF kappa B, and p38 MAP kinase may all contribute to COPD pathogenesis. ► Inhibitors of TNF alpha, IKK2 and p38 MAPK may be useful as COPD therapies.